ReviewOncotarget2016
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis.
Review in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of carbon-ion radiotherapy for the malignant melanoma: A systematic review.Cancer medicine · 2020Pooled it
- Systemic treatments for metastatic cutaneous melanoma.The Cochrane database of systematic reviews · 2018Pooled it
- Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.Journal of immunology research · 2017Pooled it
- Targeting Adaptive and Innate Immune Responses with Covalent Aptamers.Journal of the American Chemical Society · 2026Article
- The effects of patchouli alcohol and combination with cisplatin on proliferation, apoptosis and migration in B16F10 melanoma cells.Journal of cellular and molecular medicine · 2023Article
- Mannose-functionalization of reconstituted high-density lipoprotein nanoparticles improves payload delivery and enhances M2-to-M1 phenotype reprogramming of RAW 264.7 macrophages polarized by B16-F10 melanoma cells.Frontiers in drug delivery · 2023Article
- Article
- Anti-Proliferative, Pro-Apoptotic, Anti-Migrative and Tumor-Inhibitory Effects and Pleiotropic Mechanism of Theaflavin on B16F10 Melanoma Cells.OncoTargets and therapy · 2021Article
- The promise of Immuno-oncology: implications for defining the value of cancer treatment.Journal for immunotherapy of cancer · 2019Article
- Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis.Journal of Cancer · 2019Article
- Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?Therapeutic advances in medical oncology · 2019Article
- Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review.Melanoma management · 2018Review
- Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.Molecular diagnosis & therapy · 2017Article
- Carbon Ion Irradiation Suppresses Tumor Growth, Migration and Invasion in X-ray Resistant MelanomaDose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelanoma is a highly malignant tumor that develops from a neural crest derivative called melanocytes. Chemotherapy is recommended for patients with stage III/IV melanoma. Immunomodulation has also been shown to effectively improve the survival rate of such patients. In the current study, we aimed to perform a network meta-analysis on the therapeutic value of chemotherapy and immunotherapy on melanoma.
resultsTwenty randomized controlled trials (RCTs) were enrolled in the study. Our Results indicated that ipilimumab + nivolumab had the highest response rate among all therapies, pembrolizumab also had a good efficacy with an excellent tolerance. Chemotherapy had a low response rate, high adverse effects and progressive diseases qualities, therefore it is not recommended as a preferred treatment for patients with advanced melanoma.
methodsThe Cochrane library, PubMed and Embase databases were searched for relevant articles. Results of the pair-wise meta-analysis were illustrated by odd ratios (ORs) and corresponding 95% confidence intervals (CIs). Network meta-analysis was performed using a random-effects model under Bayesian framework. Results were illustrated by cumulative ORs and corresponding 95% credible interval (CrIs). The probabilities and outcomes of each treatment were ranked and summarized using the surface under the cumulative ranking curve (SUCRA).
conclusionsWe recommend pembrolizumab as the preferred treatment due to its high efficacy and low adverse effects, combination of ipilimumab and nivolumab could be used in severe symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.